Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Response Providing SuperGen Access to Technologies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SuperGen has gained access to technologies from Molecular Response under a deal announced today.

Pharmaceutical firm SuperGen will have limited access to Molecular Response's "living" cell bank of primary tumor cells, high-content imaging, and molecular characterization platforms.

Financial and other terms of the agreement were not released.

Based in Dublin, Calif., SuperGen discovers and develops cancer therapeutics in epigenetic and cell signaling modulation. San Diego-based Molecular Response develops companion diagnostics and other tools for targeted therapeutic development.

"We believe our high-resolution, high-content cell-based platforms and exclusive patient-derived primary tumor cell bank provide the best model for predicting efficacy of novel drugs," Molecular Response CEO Cyrus Mirsaidi, said in a statement. "I expect our collaboration with Supergen to set a leading example in translational medicine."

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.